TIDMSBI
RNS Number : 2135Z
SourceBio International PLC
20 May 2021
SourceBio International plc
("SourceBio", the "Company" or the "Group")
National Framework contract tender for Covid-19 testing products
and services
SourceBio International accepted for UK-wide National
Microbiology Framework (Lot 4) tender
and
Further COVID-19 Government testing approvals for Day 2 and Day
8 testing
SourceBio International plc (AIM: SBI), the international
provider of integrated state-of-the-art laboratory services and
products , announces that it has been successful with its tender
for the Lot 4 Framework Agreement under Public Health England's
("PHE") National Microbiology Framework to provide its Clinical
Laboratory Diagnostic Testing Services .
PHE's National Microbiology Framework
PHE's National Microbiology Framework is appointing suppliers to
framework agreements in four lots. Lot 4 covers Clinical Laboratory
Diagnostic Testing Services, utilising new and existing techniques
to ensure that there are consistent and affordable provision of
high quality, safe and compliant testing services which should be
delivered efficiently and effectively to support wider clinical
services. The term of the Framework Agreement for Lot 4 is for an
initial two years with the option to extend by up to a further two
years.
Under the National Microbiology Framework, participating public
health authorities across the United Kingdom can use any of the 50
qualifying companies of Lot 4 to call-off contracts to procure
goods and testing services. One of which is SourceBio, however this
agreement is not exclusive to SourceBio and does not guarantee
orders.
SourceBio continues to invest into its capacity in order to meet
the current requirements for centralised testing. The Group is well
placed to react to new strains of the virus and to respond with
speed, utilising its experience working with the Department of
Health and Social Care ("DHSC") for surge testing and in operating
mobile testing laboratories.
Further COVID-19 Government testing approvals for D2/D8
testing
The Group also announces that it has been added to the UK
Government's approved list as a private provider of day two and day
eight ("D2/D8") coronavirus testing for all international arrivals
for both SARS-CoV-2 PCR testing and SARS-CoV 2 genome sequencing
testing services.
The COVID-19 testing services provided by SourceBio meet the
DHSC's 15 minimum standards and have been reviewed by UKAS, a
national accreditation body recognised by the UK Government to
assess against international agreed standards.
From 15 February 2021, international arrivals were required to
self-isolate for 10 days on return to the UK and take a polymerase
chain reaction ('PCR') test on day two and day eight of the
passenger's quarantine period. If the day two test result is
positive and meets the DHSC sequencing criteria, it requires
sequencing in a laboratory for surveillance purposes in order to
monitor variants of concern and variants under investigation, the
results of which are reported directly back to Public Health
England. Both PCR testing and sequencing can be undertaken in the
Group's own laboratory facilities.
SourceBio has added the D2/D8 service to its COVID-19 services
with immediate effect and its tests can be
ordered directly from the Company's website: https://www.sourcebioscience.com/.
Jay LeCoque, Executive Chairman, SourceBio International, said:
"We are very encouraged with the successful tender award under Lot
4 of the Microbiology Framework and welcome the opportunity to work
with PHE and its sister organisations across the NHS and DHSC in
Wales, Scotland and Northern Ireland. We will continue to
contribute our Clinical Laboratory Diagnostic Testing Services to
help contain Covid-19 in the near-term and are pleased to
participate in creating a robust testing infrastructure
post-pandemic.
We are pleased to be supporting the COVID-19 testing efforts.
This DHSC approval with regards to day two and day eight testing
further confirms the competency of our services and positions
SourceBio International as a leading player in the market."
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Adviser and Broker) Tel: 020 3100 2000
Bidhi Bhoma
Richard Lindley
Euan Brown
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748
651 727
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Infectious Disease Testing - a range of COVID-19 testing
services for the Department of Health and Social Care (DHSC), the
NHS, Private Healthcare groups and Commercial enterprises.
Utilising various technologies (RT-qPCR, LamPore and LAMP)
SourceBio offers both screening and gold standard COVID-19 testing
and operates under the ISO: 15189 accreditation required by the
DHSC for COVID-19 test services. SourceBio offers employee testing
solutions to industry, home testing kits (including 'Fit to Fly'
and 'Test to Release' approved tests) and operates Mobile Testing
Unit laboratories to support event and venue testing.
-- Healthcare Diagnostics - histopathology and clinical
diagnostic services for the NHS and private healthcare across the
UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDGGDUGBBDGBC
(END) Dow Jones Newswires
May 20, 2021 02:00 ET (06:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024
